Decreasing affinity of CAR-T cells targeting HER2 to increase therapeutic outcome against tumors

ZHANG Hao; YE Zhenlong; QIAN Qijun

doi:10.3969/j.issn.1006-0111.2016.03.018

Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review, editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name

E-mail

Phone

Title

Content

Verification Code

Objective To investigate whether decreasing affinity of CAR-T cells can increase their therapeutic outcome or not. Methods Moderate affinity La-G3HER2-CAR and high affinity Ha-G3HER2-CAR were constructed, and electroporated to modify T cells. Western blot assay, FCM assay and the RTCA DP cytotoxic equipment were applied to test the CAR expression and cytotoxic function of CAR-T cells. Results 43000 and 58000 exogenous CD3ζ fragments were expressed by both La-G3HER2-CAR-T cells and Ha-G3HER2-CAR-T cells with 58.1% and 69.0% transfection rate respectively. High affinity Ha-G3HER2-CAR-T cells effectively killed all target tumor cells by which HER2 was expressed at variable expression levels, while moderate affinity La-G3HER2-CAR-T cells specifically killed HER2 high-level expressing SK-OV-3 and BT474 cells, and showed weaker cytotoxicity on HER2 moderate-level expressing MDA-MB-231 and HCC-202 cells, and showed no cytotoxicity on HER2 low-level expressing MCF-7 and 293 cells. The underlying mechanic investigation found that La-G3HER2-CAR-T cells and Ha-G3HER2-CAR-T cells were differentially activated by co-culture with MDA-MB-231(CD107a:8.2% vs 71.6%, IFN-γ:66.3% vs 83.4%, TNF-α:73.4% vs 94.1%). Conclusion Moderate affinity La-G3HER2-CAR-T cells have enhanced specific cytotoxicity toward target tumor cells compared to high affinity Ha-G3HER2-CAR-T cells, decreasing affinity of CAR-T cell is a promising strategy to increase the therapeutic outcome of CAR-T cell based immunotherapies.

Decreasing affinity of CAR-T cells targeting HER2 to increase therapeutic outcome against tumors

Laboratory of Viral and Gene Therapy, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 200438, China

Received Date: 2016-04-20

Rev Recd Date: 2016-05-04

Key words:

Abstract: Objective To investigate whether decreasing affinity of CAR-T cells can increase their therapeutic outcome or not. Methods Moderate affinity La-G3HER2-CAR and high affinity Ha-G3HER2-CAR were constructed, and electroporated to modify T cells. Western blot assay, FCM assay and the RTCA DP cytotoxic equipment were applied to test the CAR expression and cytotoxic function of CAR-T cells. Results 43000 and 58000 exogenous CD3ζ fragments were expressed by both La-G3HER2-CAR-T cells and Ha-G3HER2-CAR-T cells with 58.1% and 69.0% transfection rate respectively. High affinity Ha-G3HER2-CAR-T cells effectively killed all target tumor cells by which HER2 was expressed at variable expression levels, while moderate affinity La-G3HER2-CAR-T cells specifically killed HER2 high-level expressing SK-OV-3 and BT474 cells, and showed weaker cytotoxicity on HER2 moderate-level expressing MDA-MB-231 and HCC-202 cells, and showed no cytotoxicity on HER2 low-level expressing MCF-7 and 293 cells. The underlying mechanic investigation found that La-G3HER2-CAR-T cells and Ha-G3HER2-CAR-T cells were differentially activated by co-culture with MDA-MB-231(CD107a:8.2% vs 71.6%, IFN-γ:66.3% vs 83.4%, TNF-α:73.4% vs 94.1%). Conclusion Moderate affinity La-G3HER2-CAR-T cells have enhanced specific cytotoxicity toward target tumor cells compared to high affinity Ha-G3HER2-CAR-T cells, decreasing affinity of CAR-T cell is a promising strategy to increase the therapeutic outcome of CAR-T cell based immunotherapies.

HTML

Reference (16)

[1]	Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia[J]. N Engl J Med, 2014, 371(16):1507-1517.
[2]	Shen H, Laird PW. Interplay between the cancer genome and epigenome[J]. Cell, 2013, 153(1):38-55.
[3]	Roessler S, Budhu A, Wang XW. Deciphering cancer heterogeneity:the biological space[J]. Front Cell Dev Biol, 2014, 2:12.
[4]	Beavis PA, Slaney CY, Kershaw MH, et al. Reprogramming the tumor microenvironment to enhance adoptive cellular therapy[J]. Semin Immunol, 2015, 11:3.
[5]	Park HJ, Kusnadi A, Lee EJ, et al. Tumor-infiltrating regulatory T cells delineated by upregulation of PD-1 and inhibitory receptors[J]. Cell Immunol, 2012, 278(1):76-83.
[6]	Ciceri F, Bonini C, Stanghellini MT, et al. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial):a non-randomised phase Ⅰ-Ⅱ study[J]. Lancet Oncol, 2009, 10(5):489-500.
[7]	Kloss CC, Condomines M, Cartellieri M, et al. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells[J]. Nat Biotechnol, 2013, 31(1):71-75.
[8]	Caruso HG, Hurton LV, Najjar A, et al. Tuning sensitivity of CAR to EGFR density limits recognition of normal tissue while maintaining potent antitumor activity[J]. Cancer Res, 2015, 75(17):3505-3518.
[9]	Sun M, Shi H, Liu C, et al. Construction and evaluation of a novel humanized HER2-specific chimeric receptor[J]. Breast Cancer Res, 2014, 16(3):R61.
[10]	Lanitis E, Dangaj D, Hagemann IS, et al. Primary human ovarian epithelial cancer cells broadly express HER2 at immunologically-detectable levels[J]. PLoS One, 2012, 7(11):e49829.
[11]	Hapuarachchige S, Kato Y, Artemov D. Bioorthogonal two-component drug delivery in HER2(+) breast cancer mouse models[J]. Sci Rep, 2016, 6:24298.
[12]	Kulhari H, Pooja D, Shrivastava S, et al. Trastuzumab-grafted PAMAM dendrimers for the selective delivery of anticancer drugs to HER2-positive breast cancer[J]. Sci Rep, 2016, 6:23179.
[13]	左明辉, 金华君, 黎江, 等. 多靶向VEGF-EGFR的Fc融合蛋白EVP1的构建及其结合特性[J]. 中国肿瘤生物治疗杂志, 2012, 19(3):239-246.
[14]	Zhong XS, Matsushita M, Plotkin J, et al. Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI₃ kinase/AKT/Bcl-X_L activation and CD8⁺ T cell-mediated tumor eradication[J]. Mol Ther, 2010, 18(2):413-420.
[15]	Kenderian SS, Ruella M, Gill S, et al. Chimeric antigen receptor T-cell therapy to target hematologic malignancies[J]. Cancer Res, 2014, 74(22):6383-6389.
[16]	Harris DT, Kranz DM. Adoptive T cell therapies:A comparison of T cell receptors and chimeric antigen receptors[J]. Trends Pharmacol Sci, 2016, 37(3):220-230.

Message Board

Decreasing affinity of CAR-T cells targeting HER2 to increase therapeutic outcome against tumors

doi: 10.3969/j.issn.1006-0111.2016.03.018

Abstract

References

Proportional views

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Related

Proportional views